Citations

Showing 10 of 108081 citations.

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Bekaii‐Saab, Tanios , Yaeger, Rona , Spira, Alexander I. , Pelster, Meredith , Sabari, Joshua K. , Hafez, Navid , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Pant, Shubham , Bekaii-Saab, Tanios S , Pelster, Meredith S , Yan, Xiaohong , Der-Torossian, Hirak , Barve, Minal , Shetty, Aditya, Pant, Shubham

Mayo Clinic

Journal of Clinical Oncology | April 26, 2023 | Volume: 41 | Issue: 25 | Pages: 4097-4106

10.1200/jco.23.00434 | PMID 37099736 Get It

PURPOSE Adagrasib, a KRAS G12C inhibitor, has demonstrated clinical activity in patients with KRAS G12C -mutated non–small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRAS G12C mutations occur rarely in other solid tumor types. We report evaluation of the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS G12C mutation. METHODS In this phase II cohort of the KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249 ; phase Ib cohort), we evaluated adagrasib (600 mg orally twice daily) in patients with KRAS G12C -mutated advanced solid tumors (excluding NSCLC and CRC). The primary end point was objective response rate. Secondary end points included duration of response, progression-free survival (PFS), overall survival, and safety. RESULTS As of October 1, 2022, 64 patients with KRAS G12C -mutated solid tumors were enrolled and 63 patients treated (median follow-up, 16.8 months). The median number of prior lines of systemic therapy was 2. Among 57 patients with measurable disease at baseline, objective responses were observed in 20 (35.1%) patients (all partial responses), including 7/21 (33.3%) responses in pancreatic and 5/12 (41.7%) in biliary tract cancers. The median duration of response was 5.3 months (95% CI, 2.8 to 7.3) and median PFS was 7.4 months (95% CI, 5.3 to 8.6). Treatment-related adverse events (TRAEs) of any grade were observed in 96.8% of patients and grade 3-4 in 27.0%; there were no grade 5 TRAEs. TRAEs did not lead to treatment discontinuation in any patients. CONCLUSION Adagrasib demonstrates encouraging clinical activity and is well tolerated in this rare cohort of pretreated patients with KRAS G12C -mutated solid tumors.
A survey of North American physicians' clinical practices related to pharmacologic, herbal, and nutritional substances used to increase milk production
Sadovnikova, Anna , Sommers, Jan, Oberhelman, Sara S.

Mayo Clinic

No container title available | April 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.168252884.45238740/v1 Get It

Introduction Patients turn to foods, herbs, and medications to increase milk supply (i.e., galactagogues). Physicians may be asked to prescribe, recommend, or discuss perceived galactagogues despite a lack of evidence for their use. It is unclear how factors such as education, experience, and regulations influence clinical practice. The primary objective of this study was to document Canadian and US-based physicians’ attitudes towards, practice patterns surrounding, and utilization of pharmacologic, nutritional, and herbal products for the management of low milk supply. A secondary objective of this study was to determine factors that influence physicians’ decision-making with respect to the use of pharmacologic agents, foods, and vitamin, mineral, and herbal supplements for the treatment of low milk supply. Methods Physicians were recruited from two Facebook groups to complete an anonymous, online survey about their clinical use of pharmaceutical, supplemental, and nutritional substances perceived to increase milk production. The association between practice patterns and lactation medicine expertise or country for different perceived galactagogues was determined. Results A total of 307 physicians completed the primary portion of the survey. There was no difference in the proportion of physicians in Canada or the United States (US) who were defined as lactation medicine experts. Canadian physicians were more likely to prescribe metformin, levothyroxine, and domperidone, despite limited evidence of their effectiveness as galactagogues. Experts used all of the pharmacologic galactagogues. Canadians and experts were more likely than US-based and non-expert physicians, respectively, to include herbs in their practice. Numerous reasons for recommending or not recommending a given agent were cited, including patient request, personal and clinical experience, and lack of education, research, or access. Discussion The US FDA ban on domperidone affects which pharmacologic agents physicians in North America prescribe for low milk production. Despite having access to domperidone and limited evidence of their effectiveness, Canadian physicians are more likely than US physicians to also discuss, recommend, or prescribe herbal supplements as galactagogues. Conclusion In this online survey about medications, herbs, and foods commonly used in an effort to increase milk supply, Canadian and US-based physicians with and without lactation medicine expertise described their practice patterns and reported limitations in knowledge, medication access, and evidence. Though Canadian physicians prescribed domperidone without limitations, US physicians were less likely to incorporate it into clinical practice.
Anatomical and functional study of the musculus psoas major and nervus femoralis in correlation with pelvic diameters
Vojvodić, Aleksandar, Bjelogrlic, Predrag, Stijak, Lazar , Aleksić, Dubravka , Filipović, Branka , Vukomanović-Djurdjević, Biserka, Kapor, Slobodan , Matić, Aleksandar , Mihailović, Jelena M. , Puškaš, Laslo

Mayo Clinic

Vojnosanitetski pregled | April 26, 2023 | Volume: 80 | Issue: 10 | Pages: 814-820

10.2298/vsp221129025v Get It

Background/Aim. The iliopsoas muscle [musculus (m.) iliopsoas] originates from the Greek word ps?a, which means loin and represents the only muscle in the body with anatomical preconditions to simultaneously and directly contribute to the stability and movement of the trunk, pelvis, and legs. M. iliopsoas belongs to the inner thigh muscle group and forms part of the posterior abdominal wall. This muscle is the major flexor of the hip joint, and it is functionally essential for proper posture, walking, running, and other physical activities. The aim of this study was to determine the relationship between the anatomical parameters of the pelvis and nervus (n.) femoralis, as well as the relationship between the same pelvic parameters and m. psoas major. Methods. The study was conducted at the Faculty of Medicine, University of Belgrade, on cadaveric material of the Institute of Anatomy ?Niko Miljanic?. For measurement purposes, 14 cadavers were used, seven of which were male and seven female, aged 67?79 years. The measuring instruments used in this study were a ruler and an electronic digital caliper (measuring range 0?500 mm, resolution 0.01 mm). Statistical data processing was performed in the SPSS 11.0 program using the Mann-Whitney U test. Results. The results of this study indicate a significant statistical difference in pelvic width between male and female cadavers, which was observed in the reduction of the bituberal line in females, while the parameters of the bispinal line showed no significant difference between the two genders. The decrease of the bituberal line in females was followed by an increase in the width of the proximal origin with a statistically significant decrease in the length of the proximal origin of the m. psoas major. Furthermore, the vertical distance of n. femoralis from the exit point of the muscle to the bispinal line was significantly reduced in the male cadavers. Conclusion. Based on our results, we can assume that, in most cases, due to the smaller bituberal and bispinal line or narrower pelvis, a shorter proximal attachment of the m. psoas major will occur with greater width (L2?L5 level) in the female than in the male gender, resulting in a longer vertical distance of n. femoralis. Such results indicate a close correlation between the anatomical parameters of the m. psoas major, which may affect the distance of n. femoralis exit from the muscle.
The Utilization of Fresh Frozen Cartilage in Asian Rhinoplasty: A New Approach
Wan, Rou , Weissman, Joshua P. , Ullrich, Peter J. , Joshi, Chitang , Williams, Tokoya, Galiano, Robert D.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 26, 2023 | Volume: 11 | Issue: 4 | Pages: e4903

10.1097/gox.0000000000004903 | PMID 37124386 Get It

Summary: Asian rhinoplasty generally requires augmentation procedures rather than reduction. Alloplastic grafts are fraught with higher complication rates. Autologous cartilage grafts are safer. However, Asian patients typically do not have adequate septal cartilages, and other autologous cartilage grafts may cause surgical site morbidities, prolonged surgical time, and complications, including warping and infection. Asian rhinoplasties were performed using fresh frozen cartilage by the senior author. Patients’ demographics and medical histories were recorded. Anthropometric measurements (nasofrontal angle, nasofacial angle, nasolabial angle, and Goode ratio) were taken on two-dimensional photographs. FACE-Q scales were used to assess patient-reported outcomes. Five Asian patients underwent rhinoplasty using the fresh frozen cartilage and were followed up for an average period of 14.2 ± 3.35 months. There was no resorption, warping, or infection. Anthropometric measurements showed no significant changes 2–4 months or 8–20 months after surgery. At the time of the 1-year follow-up, mean FACE-Q Satisfaction with Nose, and Satisfaction with Nostrils scores improved from 35.2 ± 10.06 to 60 ± 15.48 (P = 0.0002), and 42.6 ± 20.31 to 59.8 ± 38.21 (P = 0.12), respectively. Fresh frozen cadaveric cartilage is a novel option for Asian rhinoplasty. Our study demonstrated its safety and satisfying surgical outcomes.
Global hemodialysis vascular access care: Three decades of evolution
Hassanein, Mohamed , Radhakrishnan, Yeshwanter , Garcilazo, Nora H. Hernandez , Khor, Si Yuan , Norouzi, Sayna , Anvari, Evamaria , Shingarev, Roman , Vachharajani, Tushar J. , Radhakrishnan, Yeshwanter

Mayo Clinic

The Journal of Vascular Access | April 26, 2023 | Volume: 26 | Issue: 1 | Pages: 5-14

10.1177/11297298231159251 | PMID 37098769 Get It

The development of vascular access for hemodialysis has come a long way since 1943 when the first hemodialysis treatment was performed in humans by connecting an artery and vein using an external glass canula. Since then, vascular access care has evolved robustly through contributions from numerous countries and professional nephrology societies, worldwide. To understand the global distribution and contribution of different specialties to medical literature on dialysis vascular access care, we performed a literature search from 1991 to 2021 and identified 2768 articles from 74 countries. The majority of publications originated from the United States (41.5%), followed by China (5.1%) and the United Kingdom (4.6%). Our search results comprise of observational studies (43%), case reports/series (27%), review articles (16.5%) and clinical trials (12%). A large proportion of articles were published in Nephrology journals (49%), followed by General Medicine (14%), Surgery (10%), Vascular Medicine (8%), and Interventional Radiology journals (4%). With the introduction of interventional nephrology, nephrologists will be able to assume the majority of the responsibility for dialysis vascular access care and above all maintain a close interdisciplinary collaboration with other specialties to provide optimum patient care. In this review article, we discuss the history, evolving knowledge, challenges, educational opportunities, and future directions of dialysis vascular access care, worldwide.
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats
Adams, Leon A. , Schulte, Phillip J. , Allen, Alina M.

Mayo Clinic

Hepatology | April 26, 2023 | Volume: 78 | Issue: 4 | Pages: 1029-1031

10.1097/hep.0000000000000419 | PMID 37185880 Get It

Microfluidic ‘Brain-on Chip’ Systems to Supplement Neurological Practice: Development, Applications and Considerations
Jarrah, Ryan , Nathani, Karim Rizwan , Bhandarkar, Shaan , Ezeudu, Chibuze S., Nguyen, Ryan T. , Amare, Abrham, Aljameey, Usama A., Jarrah, Sabrina I., Bhandarkar, Archis R. , Fiani, Brian , Nathani, Karim Rizwan , Nguyen, Ryan T

Mayo Clinic

Regenerative Medicine | April 26, 2023 | Volume: 18 | Issue: 5 | Pages: 413-423

10.2217/rme-2022-0212 | PMID 37125510 Get It

Transcatheter Aortic Valve Replacement Prognostication with Augmented Mean Arterial Pressure
Agasthi, Pradyumna , Seri, Amith Reddy , Barry, Timothy , Shanbhag, Anusha , Wang, Yuxiang , Eleid, Mackram F. , Fortuin, David, Sweeney, John P., Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Freeman, William K., Naqvi, Tasneem Z. , Holmes, David R. , Appleton, Christopher P., Arsanjani, Reza , Seri, Amith R, Barry, Timothy , Arsanjani, Reza , Chao, Chieh‐Ju

Mayo Clinic

Journal of Cardiovascular Development and Disease | April 26, 2023 | Volume: 10 | Issue: 5 | Pages: 192

10.3390/jcdd10050192 | PMID 37233159 Get It

Background: Post-transcatheter aortic valve replacement (TAVR) patient outcome is an important research topic. To accurately assess post-TAVR mortality, we examined a family of new echo parameters (augmented systolic blood pressure (AugSBP) and arterial mean pressure (AugMAP)) derived from blood pressure and aortic valve gradients. Methods: Patients in the Mayo Clinic National Cardiovascular Diseases Registry-TAVR database who underwent TAVR between 1 January 2012 and 30 June 2017 were identified to retrieve baseline clinical, echocardiographic and mortality data. AugSBP, AugMAP and valvulo-arterial impedance (Zva) (Zva) were evaluated using Cox regression. Receiver operating characteristic curve analysis and the c-index were used to assess the model performance against the Society of Thoracic Surgeons (STS) risk score. Results: The final cohort contained 974 patients with a mean age of 81.4 ± 8.3 years old, and 56.6% were male. The mean STS risk score was 8.2 ± 5.2. The median follow-up duration was 354 days, and the one-year all-cause mortality rate was 14.2%. Both univariate and multivariate Cox regression showed that AugSBP and AugMAP parameters were independent predictors for intermediate-term post-TAVR mortality (all p < 0.0001). AugMAP1 < 102.5 mmHg was associated with a 3-fold-increased risk of all-cause mortality 1-year post-TAVR (hazard ratio 3.0, 95%confidence interval 2.0–4.5, p < 0.0001). A univariate model of AugMAP1 surpassed the STS score model in predicting intermediate-term post-TAVR mortality (area under the curve: 0.700 vs. 0.587, p = 0.005; c-index: 0.681 vs. 0.585, p = 0.001). Conclusions: Augmented mean arterial pressure provides clinicians with a simple but effective approach to quickly identify patients at risk and potentially improve post-TAVR prognosis.
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis
Foran, James M. , Sun, Zhuoxin , Lai, Catherine , Fernández, Hugo F. , Cripe, Larry D., Racevskis, Janis, Luger, Selina M. , Paietta, Elisabeth , Zhang, Yanming , Bennett, John M. , Levine, Ross L. , Rowe, Jacob M. , Litzow, Mark R. , Tallman, Martin S. , Lai, Catherine , Ketterling, Rhett P. , Lazarus, Hillard M.

Mayo Clinic

Cancer | April 26, 2023 | Volume: 129 | Issue: 16 | Pages: 2479-2490

10.1002/cncr.34807 | PMID 37185873 Get It

AbstractBackgroundObesity (body mass index [BMI] ≥30 kg/m2) is an important epidemiological risk factor for developing acute myeloid leukemia (AML). Therefore, the authors studied the association of obesity with clinical and genetic phenotype and its impact on outcome in adults with AML.MethodsThe authors analyzed BMI in 1088 adults who were receiving intensive remission induction and consolidation therapy in two prospective, randomized therapeutic clinical trials of the Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network: E1900 (ClinicalTrials.gov identifier NCT00049517; patients younger than 60 years) and E3999 (ClinicalTrials.gov identifier NCT00046930; patients aged 60 years or older).ResultsObesity was prevalent at diagnosis (33%) and, compared with nonobesity, was associated with intermediate‐risk cytogenetics group (p = .008), poorer performance status (p = .01), and a trend toward older age (p = .06). Obesity was not associated with somatic mutations among a selected 18‐gene panel that was tested in a subset of younger patients. Obesity was not associated with clinical outcome (including complete remission, early death, or overall survival), and the authors did not identify any patient subgroup that had inferior outcomes based on BMI. Obese patients were significantly more likely to receive <90% of the intended daunorubicin dose despite protocol specification, particularly in the E1900 high‐dose (90 mg/m2) daunorubicin arm (p = .002); however, this did not correlate with inferior overall survival on multivariate analysis (hazard ratio, 1.39; 95% confidence interval, 0.90–2.13; p = .14).ConclusionsObesity is associated with unique clinical and disease‐related phenotypic features in AML and may influence physician treatment decisions regarding daunorubicin dosing. However, the current study demonstrates that obesity is not a factor in survival, and strict adherence to body surface area‐based dosing is not necessary because dose adjustments do not affect outcomes.
Staff Successes and Challenges with Telecommunications-Facilitated Patient Care in Hybrid Hospital-at-Home during the COVID-19 Pandemic
Zawada, Stephanie , Sweat, Jeffrey, Paulson, Margaret R. , Maniaci, Michael J. , Zawada, Stephanie K , Maniaci, Michael J , Paulson, Margaret R

Mayo Clinic

Healthcare | April 26, 2023 | Volume: 11 | Issue: 9 | Pages: 1223

10.3390/healthcare11091223 | PMID 37174766 Get It

Technology-enhanced hospital-at-home (H@H), commonly referred to as hybrid H@H, became more widely adopted during the COVID-19 pandemic. We conducted focus group interviews with Mayo Clinic staff members (n = 14) delivering hybrid H@H in three separate locations—a rural community health system (Northwest Wisconsin), the nation’s largest city by area (Jacksonville, FL), and a desert metropolitan area (Scottsdale, AZ)—to understand staff experiences with implementing a new care delivery model and using new technology to monitor patients at home during the pandemic. Using a grounded theory lens, transcripts were analyzed to identify themes. Staff reported that hybrid H@H is a complex care coordination and communication initiative, that hybrid H@H faces site-specific challenges modulated by population density and state policies, and that many patients are receiving uniquely high-quality care through hybrid H@H, partly enabled by advances in technology. Participant responses amplify the need for additional qualitative research with hybrid H@H staff to identify areas for improvement in the deployment of new models of care enabled by modern technology.